Has Andrei Carasca, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,336 in general payments to Andrei Carasca, MD across 101 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Andrei Carasca, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Andrei Carasca, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Andrei Carasca, MD

Clinical Neurophysiology · New York, NYNPI 1992703391

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.8% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,682 and has fallen 85.6% since, to $241 in 2024.

$2,336in general payments, 2019–2025

Across 101 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

UCB, Inc.$511
Acadia Pharmaceuticals Inc$476
Amneal Pharmaceuticals LLC$258
Sanofi$180
AbbVie$166
Novartis$111
plus $633 from 12 others

What the payments were for

Speaking & faculty fees$994%
Food & beverage$2,23796%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
UCB, Inc.	22	$511
Acadia Pharmaceuticals Inc	11	$476
Amneal Pharmaceuticals LLC	10	$258
Sanofi	10	$180
AbbVie	4	$166
Novartis	6	$111
Acorda Therapeutics, Inc	5	$99
Sunovion Pharmaceuticals Inc.	6	$89
MDD US Operations, LLC	4	$89
Supernus Pharmaceuticals, Inc.	5	$82
Vertical Pharmaceuticals, LLC	5	$67
Avanir Pharmaceuticals, Inc.	3	$47
Banner Life Sciences, LLC	2	$37
Biogen	2	$34
Teva Pharmaceuticals USA, Inc.	2	$29
Adamas Pharmaceuticals, Inc.	2	$27
EDW Pharma, Inc.	1	$20
Amgen	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NUPLAZID$341
RYTARY$125
Neupro$125
UBRELVY$125

How this compares

$2,336 in reported general payments places this provider in the 65th percentile of 35 clinical neurophysiology providers in New York.

See all clinical neurophysiology providers in New York →

Medicare billing

Part B allowed, 2024

$44,702

Medicare patients

138

Services billed

275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Naloxone Hcl	72	$10,093
Oxycodone Hcl	373	$7,132
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	249	$5,754
Diclofenac Sodium ErDiclofenac Sodium	262	$4,280
Gabapentin	311	$3,470
Tizanidine Hcl	596	$2,580
EndocetOxycodone Hcl/Acetaminophen	57	$2,458
Pregabalin	38	$1,307
Morphine Sulfate ErMorphine Sulfate	23	$1,031
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine	59	$1,023
Zolpidem Tartrate	146	$1,003
Levetiracetam	38	$853
Tramadol Hcl ErTramadol Hcl	11	$806
Ibuprofen	91	$723
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	47	$603

Paid to pharmacies, not to this prescriber.

Other clinical neurophysiology in New York

Alcibiades RodriguezNew York$714K
Jessica Robinson-PappNew York$28K
Madeline FieldsNew York$5K
Agnieszka KokoszkaNew York$5K
Cristina DraftaNew York$2K
Kiril KiprovskiNew York$488
James YoungNew York$256
Jonathan VictorNew York$124
Samuel RapoportNew York$16
Farhad Kadkhodaei ElyaderaniBronx$156K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →